Ask the expert: How will Brexit affect Parkinson’s drugs and research?
Author: Simge Eva DoganPublished: 30 January 2020
Prep: Cook: Serves:
The UK is due to
formally leave the European Union this week. In the second in our series where
we ask experts about the biggest issues facing the Parkinson’s community, Dr
Kieran Breen of the European Medicines Agency Committee for Advanced Therapies gives
his views on the likely impact of Brexit – from the availability of Parkinson’s
medication to international research collaboration
First of all, could you explain to our readers how
Brexit might affect people with Parkinson’s? Will there be an impact on the
supply of medications?
It’s very difficult to look into the future, but yes, the
availability of the therapies and drugs for people with Parkinson’s may be
impacted. We don’t know how things are going to develop in the transition period
over the next 11 months, but it could be that when drugs are coming through
customs they are delayed at the point of entry to the country.
I would imagine that because pharmaceuticals are so
important to the lives of people in the UK with Parkinson’s and every other
condition, that the manufacturing standards are going to stay the same here as
with the rest of Europe.
What might happen to Parkinson’s drugs manufacturing in
At the moment, within Europe, the quality of drug
manufacture is the same throughout the 28 countries. The manufacturing is
usually assessed at a local level, so in the UK that would be the Medicines and
Healthcare products Regulatory Agency (MHRA), which is responsible for drug
If the MHRA assess and approve a drug at a manufacturing
site, it can go anywhere to 28 countries. However, come Brexit, what will
happen is that will no longer be the case. Any drugs manufactured in the UK
cannot automatically be sent to the 27 countries and vice versa.
Theoretically what would happen in the case of a hard Brexit is somebody from the UK will have to go to wherever the drug is manufactured and assess the quality of the manufacturing process. It’s unlikely that this will happen, but it’s a possibility.
Will Brexit impact Parkinson’s drug trials?
Once the UK is no longer in the EU, it will be less likely
that drug trials will be carried out in the UK, because the agreed standards may
be different. Also, if companies want to license a new drug, will they submit
the marketing authorisation application to the European Medicines Agency (EMA),
which is around 600 million people, or submit it to the UK, which is 60 million
people? Well, it’s a no brainer that companies are more likely to submit to the
EU funding supports a substantial amount of medical research in the UK. What effect do you think that Brexit will have for the future of Parkinson’s research and innovation in the UK?
There are two sources of funding
in the UK for Parkinson’s research – charity funding and government funding.
With government funding you can never tell what’s going to come up by the next
budget, but UK charities will continue to fund research. I don’t think Brexit
will have a significant impact on that.
The main area where there is
going to be a problem is European research funding. The European Commission
I don’t know off-hand how much of that goes to Parkinson’s.
Once Brexit happens, UK
researchers will no longer have access to EU funding, so it will choke off the
finance but it will also provide a barrier to international interaction. Interacting
with other people and exchanging ideas is a really important part of research. International
collaboration facilitates the development of new therapies, treatments,
diagnostic models and really increases the understanding of Parkinson’s.
What’s your advice for people in the Parkinson’s
community wondering how best to prepare for these changes?
With Brexit, who knows what’s going to happen? Patient organisations and patients’ collaborators need to
keep a very close eye on what’s happening from a Brexit perspective and make
sure they are talking to the right people so that their voices are heard.
Patients and healthcare professionals need to work with organisations to make sure that the agenda is moved forward – and make sure that MPs are aware of the implications of Brexit from a patient’s perspective. It’s really important that the topic of drug availability remains on the agenda.
Need to know: Dr Kieran Breen is a UK-based pharmacologist. He worked at Parkinson’s UK for nine years as Director of Research & Innovation. He was nominated by the EPDA to join the European Medicines Agency Committee for Advanced Therapies in 2013 – a group which deals with the next generation of therapies.
At a glance: Parkinson’s and Brexit
Brexit may affect the availability of Parkinson’s therapies and drugs in the UK.
It will be less likely that drug trials are carried out in the UK after Brexit.
After Brexit, UK researchers will no longer have access to EU funding which may affect both the financing of new studies and international collaboration.
Parkinson’s organisations need to make sure that patient voices are heard during the transition and lobby the government to ensure that drug availability remains on the agenda.
Plant-based compounds could treat chronic pain in Parkinson’s, study finds
A six-year study has found that chronic pain in people with Parkinson’s is linked to a gene involved with how the brain responds to cannabis compounds. The investigation examined why some people with the condition experience persistent pain – and the impact it has on their work, daily life and social relationships. Conducted by researchers at Manchester’s Salford Royal Foundation Trust, UK, and funded by Parkinson’s UK, it is the largest study to investigate chronic pain in people with Parkinson’s. Dr Monty Silverdale, consultant neurologist at Greater Manchester Centre, said: “This study is significant because it shows the important role of genetics in chronic pain in Parkinson’s. “Our findings suggest that cannabis-based compounds may be worth investigating as a treatment for pain in Parkinson’s.”
Could playing table tennis help reduce Parkinson’s symptoms?
Researchers at Fukuoka University, Japan, have found that playing table tennis may help alleviate motor symptoms in Parkinson’s. As part of the study, 12 people with Parkinson’s with an average age of 73 played a five-hour session of table tennis every week for a period of six months. The sessions were developed specifically for people with the condition by experienced table tennis players from the university’s department of sports science. The participants were evaluated after three months and at the end of the study. At both evaluations, participants had reduced symptoms – showing improvement in speech, handwriting, walking and hand tremors. Two participants reported side-effects of backache and falling. Study author Ken-ichi Inoue, MD, of Fukuoka University said: “While this study is small, the results are encouraging because they show ping pong, a relatively inexpensive form of therapy, may improve some symptoms of Parkinson’s disease. A much larger study is…
‘Dopamine-boosting’ BT13 molecule could be used to slow Parkinson’s
Researchers have discovered that a molecule called BT13 could have potential to treat Parkinson’s. The study, conducted by scientists from the University of Helsinki, Finland, found that mice injected with the BT13 molecule had an increase in dopamine levels in the brain. Their findings also suggested that the molecule could lead to a new drug treatment to protect the brain cells that produce dopamine. Dopamine helps coordinate movement, but people with Parkinson’s have normally lost between 70 and 80% of the brain cells that produce the neurotransmitter when they are diagnosed with the condition. Professor David Dexter, Deputy Director of Research at Parkinson’s UK – which co-funded the study – said: “People with Parkinson’s desperately need a new treatment that can stop the condition in its tracks, instead of just masking the symptoms. “More research is needed to turn BT13 into a treatment to be tested in clinical trials, to…